Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting
October 17 2022 - 7:00AM
Talaris Therapeutics, Inc. (Nasdaq: TALS), a
late-clinical stage cell therapy company developing therapies with
the potential to transform the standard of care in solid organ
transplantation and severe immune and blood disorders, today
announced upcoming data presentations at the American Society of
Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in
Orlando, Fla.
Talaris will present data on the makeup of patients’ peripheral
blood mononuclear cells (PBMCs) following treatment with FCR001 in
a subgroup of living donor kidney transplant (LDKT) patients
enrolled in the Company’s Phase 3 FREEDOM-1 trial. A second
presentation reflects findings from urinary cell mRNA profiling of
a subgroup of Phase 2 patients.
The following are specific details regarding Talaris’ oral
presentations:
Title: “A regimen of nonmyeloablative
conditioning and CD8+/TCR- facilitating cells tips the balance
towards immune down-regulation and away from cytopathic activity in
kidney allograft recipients”Presenter: John Lee,
Weill Cornell MedicineNumber:
SA-OR48Session: Transplantation: Clinical Outcomes
and BiomarkersDate & Time: Saturday, November
5, 2022, 5:33 p.m. ETLocation: Orange County
Convention Center, West Building, Room W240
Title: “Immune cell transcriptome in
living-donor kidney transplant patients tolerized with allo-HSCT
cell therapy”Presenter: Jennifer McDaniels,
University of Maryland, BaltimoreNumber: SA-OR50
Session: Transplantation: Clinical Outcomes and
Biomarkers Date & Time: Saturday, November 5,
2022, 5:51 p.m. ETLocation: Orange County
Convention Center, West Building, Room W240
About Talaris TherapeuticsTalaris Therapeutics,
Inc. is a late-clinical stage cell therapy company developing
therapies with the potential to transform the standard of care in
solid organ transplantation and severe immune and blood disorders.
Talaris maintains corporate offices in Boston, MA, a GMP cell
processing facility in Louisville, KY, and research and development
laboratories in Houston, TX.
Cautionary Note Regarding Forward-Looking
Statements This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
implied and express statements regarding Talaris Therapeutics,
Inc.’s (“Talaris,” the “Company,” “we,” or “our”) strategy,
business plans and focus; the progress and timing of the
preclinical and clinical development of Talaris’ programs,
including FCR001 and the rate of enrollment for its clinical
trials; expectations regarding the timing and data from the planned
clinical update of FREEDOM-1, FREEDOM-2 or FREEDOM-3, including
potential safety, tolerability and therapeutics effects;
expectations around the anticipated contribution of the members of
Talaris’ board of directors and executives to its operations and
progress; and expectations regarding Talaris’ growth as a company
and use of capital, expenses and other financial results during the
second quarter ended on June 30, 2022 and in the future as well as
Talaris’ expected cash runway through 2024. The words “may,”
“might,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,”
“predict,” “future,” “project,” “potential,” “continue,” “target”
or the negative of these terms and similar words or expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, risks associated
with: the impact of COVID-19 on countries or regions in which the
Company has operations or does business, as well as on the timing
and anticipated timing and results of its clinical trials, strategy
and future operations, including the expected timing and results
from FREEDOM-1; the risk that the results of Talaris’ clinical
trials, including the early data from the FREEDOM-1 study, may not
be predictive of future results in connection with future clinical
trials; the Company’s expectations regarding the potential urinary
biomarker of immune quiescence, the Company’s ability to
successfully demonstrate the safety and efficacy of its drug
candidates; the timing and outcome of Talaris’ planned interactions
with regulatory authorities; and obtaining, maintaining and
protecting its intellectual property. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in the Company’s Quarterly Report on Form
10-Q for the quarter ended June 30, 2022, as well as any subsequent
filings with the Securities and Exchange Commission. In addition,
any forward-looking statements represent Talaris’ views only as of
today and should not be relied upon as representing our views as of
any subsequent date. Talaris explicitly disclaims any obligation to
update any forward-looking statements. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Media ContactLisa RaffenspergerTen Bridge
Communicationslisa@tenbridgecommunications.com(617) 903-8783
Investor ContactChris BrinzeyICR
Westwickechris.brinzey@westwicke.com(339) 970-2843
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Sep 2023 to Sep 2024